Skip to content

Protease inhibitor monotherapy in clinical practice: valid option for undetectable patients

Viral load testing: once a year proves adequate in lower-income Asia study

Resistance tests useful for patients with very low viral loads

Once-daily darunavir effective and less toxic than twice-daily in experienced patients without prior darunavir resistance: ODIN

Second-line ART in South Africa shows good results

New resistance becoming rarer as more patients achieve undetectable HIV viral load

Most NNRTI-experienced patients in southern Africa will benefit from etravirine

TB, pregnancy, most common reasons for treatment changes in African study

Full results of DART lab monitoring study published